The Global ENT Disorder Treatment Market, by Treatment Type (Devices (Hearing Aid Devices, Voice Prosthesis, Nasal Splints, Hearing Implants and Others) and Drug Type (Antibiotics, Antihistamines, Steroids, Anti-inflammatory Drugs, Others)), By Organ Type (Ear, Nose, and Throat), by End User (Hospitals, Clinics, Ambulatory Surgical Centers, Home Care Settings, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 9,521.1 million in 2016 and is projected to exhibit a CAGR of 3.2% over the forecast period (2017–2025).
The ENT Disorders treatment market is expected to gain significant traction with increasing incidence of ENT disorders and increasing environmental pollution globally. According to an article published by Harvard Medical School and Teaching Hospital, 2017, over 360 million people across the globe are suffering from hearing loss and over half of this population can be treated with proper medication and care.
Development novel treatments for ENT disorders through extensive R&D is expected to be a major factor driving the global ENT disorder treatment market growth Manufacturers are focusing on development new and innovative treatments and therapies for ENT disorders for both adult and pediatric segments, in order to maintain their market share. For instance, Otonomy, Inc. — a U.S. based drug manufacturer — received FDA approval for OTIPRIO (ciproflaxin otic suspension) in December 2015, for treatment of pediatric patients suffering with bilateral otitis media with effusion. In May 2012, Meda Pharmaceuticals received FDA approval for dymista (azelastine hydrochloride and fluticasone propionate) for the treatment of seasonal allergic rhinitis that can be consumed by intranasal administration or sprayed suspension. Furthermore, in June 2017, Inspire Medical Systems received FDA approval for Inspire 3028 neurostimulator for the treatment of obstructive sleep apnea.
Key players are continuously focusing on developing and updating their products with new technologies to treat various types of disorders. Market players are conducting clinical trials and a large number of treatment drugs and devices are in pipeline for approvals. For instance, in February 2018, Tusker Medical announced their first patient enrollment for pivotal clinical trial for tympanostomy tube replacement that is performed for recurrent ear infections or persistent fluid in the middle ear. Browse 42 Market Data Tables and 36 Figures spread through 161 Pages and in-depth TOC on “Global ENT Disorder Treatment Market”- by Treatment Type (Devices (Hearing Aid Devices, Voice Prosthesis, Nasal Splints, Hearing Implants and Others) and Drug Type(Antibiotics, Antihistamines, Steroids, Anti-inflammatory Drugs, Others)), By Organ Type (Ear, Nose and Throat), by End User (Hospitals, Clinics, Ambulatory Surgical Centers, Home Care Settings and Others), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Global Forecast to 2025
To know the latest trends and insights prevalent in the ENT disorder treatment market, click the link below:
Key players are focusing on strategic merger and acquisition strategies for development and commercialization of novel ENT therapeutics and medical devices. For instance, December 2017, Entellus Medical, Inc. — a leader in ENT drugs segment — entered a definitive merger agreement with Stryker Corporation for development of effective ENT solutions through collaboration. Moreover, in in July 2017, Entellus Medical acquired Spirox, Inc. a privately held company that manufactures, develops and markets ENT medical devices.
Key Takeaways of the ENT Disorder Treatment Market:
Some of the major players operating in the global ENT disorder treatment market include Sanofi, AstraZeneca plc, Novartis AG, Pfizer Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Pharmaceuticals, Otonomy Inc., Merck & Co., Dr. Reddys Laboratories Ltd., Allergan plc, Cochlear Ltd., Sonova Holding AG, Siemens Healthcare, Starkey Laboratories Inc., William Demant Holding A/S, Widex A/S, GN ReSound A/S, Sonic Innovations Inc., Panasonic Corp., Beltone, Rexton Inc., Avada Hearing Care, Miracle-Ear Inc., MED-EL GmbH, Nuear Hearing Aids Inc., Audiosync Inc., Bernafon, American Hearing Systems Inc., Unitron Hearing Inc., and Zounds Inc.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.